May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Treatment of Hemifacial Spasm With Botulinum Toxin: Our Experience
Author Affiliations & Notes
  • M. Al Oum
    Department of Ophthalmology, Insubria University, Varese, Italy
  • L. Cerri
    Department of Ophthalmology, Insubria University, Varese, Italy
  • S. Donati
    Department of Ophthalmology, Insubria University, Varese, Italy
  • L. Venco
    Department of Ophthalmology, Insubria University, Varese, Italy
  • C. Azzolini
    Department of Ophthalmology, Insubria University, Varese, Italy
  • Footnotes
    Commercial Relationships  M. Al Oum, None; L. Cerri, None; S. Donati, None; L. Venco, None; C. Azzolini, None.
  • Footnotes
    Support  no
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 5261. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      M. Al Oum, L. Cerri, S. Donati, L. Venco, C. Azzolini; Treatment of Hemifacial Spasm With Botulinum Toxin: Our Experience. Invest. Ophthalmol. Vis. Sci. 2008;49(13):5261.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : to assess the efficacy of muscolar injection of botulinum toxin for the treatment of primary and secondary hemifacial spasm.Materials and

Methods: : 31 patients with hemifacial spasm were treated with botulinum toxin type A injections (Botox, Allergan, Irvine CA, USA). The mean age of the patients was 76.4 years old (50-93 years old). Patients presented hemifacial spasm for a mean of 50.5 months (6-180 months) before the treatments. Every treatment consisted in an injection of 2.5 U.I. of botulin toxin on 6 sites in the interested hemiface. All patients received their first injection between june 1993 and august 2004. 22 patients (71%) were treated for more than one year. All patients underwent a complete ophthalmologic and neurologic examinations before and after the treatments with a mean follow-up of 42 months (12-168 months).

Results: : effectiveness of the therapy persisted for a mean of 3 months (1-6 months) after each treatment. Two (9%) of the 22 patients treated for more than one year had a complete remission of the pathology and two (9%) preferred surgical treatment after 5 years treatments. We reported the following complications in 4 patients: lachrymation, lagophtalmos, cheratitis, dry eye, diplopia, inferior palpebral ectropion and superior palpebral ptosis .

Keywords: clinical (human) or epidemiologic studies: outcomes/complications • eyelid • neuro-ophthalmology: diagnosis 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×